Lomitapide modifies high-density lipoprotein function in homozygous familial hypercholesterolaemia

Lomitapide modifies high-density lipoprotein function in homozygous familial hypercholesterolaemia

Abstract Background Lomitapide reduces plasma low-density lipoprotein cholesterol (LDL-C) and is approved for the treatment of homozygous familial hypercholesterolemia (HoFH). This study aims to determine the effect of lomitapide on HDL and cholesterol efflux in a cohort of patients with HoFH. Patie...

Full description

Saved in:
Bibliographic Details
Main Authors: Anouar Hafiane, Annalisa Ronca, Matteo Incerti, Alessandra Rossi, Matteo Manfredini, Elda Favari
Format: Article
Language:English
Published: BMC 2025-04-01
Series:European Journal of Medical Research
Subjects:
Apo B
Cholesterol efflux capacity
HDL cholesterol
Homozygous familial hypercholesterolaemia
Lomitapide
LDL cholesterol
Online Access:https://doi.org/10.1186/s40001-025-02439-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40001-025-02439-0

Similar Items